<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888378</url>
  </required_header>
  <id_info>
    <org_study_id>HY02-002</org_study_id>
    <nct_id>NCT03888378</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled Study of the Efficacy and Safety of HY02 Ointment in Subjects With Inflamed Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hovione Scientia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hovione Scientia Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of two strengths of HY02 Ointment versus Vehicle&#xD;
      administered twice daily for twelve weeks in subjects with a diagnosis of Inflamed Meibomian&#xD;
      Gland Dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Care provider is a designated dosing coordinator who will be unblinded for this study. Both participant and investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Vascular Engorgement in 1% HY02 Ointment compared to vehicle at week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes in Vascular Engorgement at the study eyelid margin are graded on a 5-point scale (0-4) with 0 representing minimal vascular engorgement and 4 representing maximal vascular engorgement. A lower score represents a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Eye Discomfort Visual Analogue Score (VAS) at week 12 in the 1% HY02 Ointment arm compared to vehicle</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Eye discomfort will be evaluated on a subject reported visual analog scale. The scores range from 0 (no discomfort) to 100 (maximal discomfort). Lower score indicate a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Vascular Engorgement in 0.3% HY02 Ointment compared to vehicle at week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes in Vascular Engorgement at the study eyelid margin are graded on a 5-point scale (0-4) with 0 representing minimal vascular engorgement and 4 representing maximal vascular engorgement. A lower score represents a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Eye Discomfort Visual Analogue Score (VAS) at week 12 in the 0.3% HY02 Ointment arm compared to vehicle</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Eye discomfort will be evaluated on a subject reported visual analog scale. The scores range from 0 (no discomfort) to 100 (maximal discomfort). Lower score indicate a better outcome for the subject.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>MGD-Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>0.3% Topical Minocycline Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% Topical Minocycline Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Vehicle Ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Topical Minocycline Ointment</intervention_name>
    <description>0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction</description>
    <arm_group_label>0.3% Topical Minocycline Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 0.3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Topical Minocycline Ointment</intervention_name>
    <description>1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction</description>
    <arm_group_label>1% Topical Minocycline Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Vehicle Ointment</intervention_name>
    <description>Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction</description>
    <arm_group_label>Topical Vehicle Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 0%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At Visit 1, individuals of any gender or any race will be eligible for study&#xD;
             participation if they:&#xD;
&#xD;
               1. Have provided written informed consent prior to any study procedures.&#xD;
&#xD;
               2. Are 18 years of age or above.&#xD;
&#xD;
               3. Have a clinical diagnosis of moderate to severe MGD and who meet the following&#xD;
                  criteria, in a qualifying eyelid, at both Visit 1 (Screening) and Visit 2&#xD;
                  (Randomization) examinations:&#xD;
&#xD;
                    1. Clinical sign severity score of at least 2 (moderate) on vascular&#xD;
                       engorgement at the eyelid margin and&#xD;
&#xD;
                    2. Clinical sign severity score of at least 2 (moderate) on plugging of the&#xD;
                       meibomian glands.&#xD;
&#xD;
                    3. Eye Discomfort Symptom score of ≥ 40 using VAS (0-100 point scale)&#xD;
&#xD;
               4. Meet the following criteria, in a qualifying eye (same eye that qualifies for&#xD;
                  Inclusion #3), at both the Visit 1 (Screening) and Visit 2 (Randomization)&#xD;
                  examinations:&#xD;
&#xD;
                    1. Fluorescein corneal staining (FCS) total score ≥ 3 in the inferior, central,&#xD;
                       and nasal region combined score (NEI/Industry Workshop sections 1, 4 and 5&#xD;
                       with 0-9 scale)&#xD;
&#xD;
                    2. Schirmer score of &gt;7 mm without topical anesthesia&#xD;
&#xD;
               5. Are willing and able to follow instructions and can be present for the required&#xD;
                  study visits for the duration of the study.&#xD;
&#xD;
               6. Have a BCVA, using corrective lenses if necessary, in both eyes of at least +0.7&#xD;
                  as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) or modified&#xD;
                  ETDRS.&#xD;
&#xD;
               7. If female, are non-pregnant, non-lactating and women of childbearing potential&#xD;
                  (WOCBP) must be using an acceptable method of birth control [e.g., an&#xD;
                  Intrauterine Contraceptive Device (IUCD) with a failure rate of &lt;1%, hormonal&#xD;
                  contraceptives, or a barrier method] for the duration of the study. If a female&#xD;
                  subject is currently abstinent, they must agree to use one of the acceptable&#xD;
                  methods of birth control before they become sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In order for subjects to be eligible at Visit 1 they may not:&#xD;
&#xD;
          1. Have presence of inflammation and/or active structural change in the iris or anterior&#xD;
             chamber.&#xD;
&#xD;
          2. Have lid structural abnormalities such as entropion or ectropion.&#xD;
&#xD;
          3. In the eyelid that qualifies (based on Inclusion #3), have grade level 4 (Obstructed)&#xD;
             on Character of Secretion of Meibomian Glands or grade level 4 (No glands are&#xD;
             expressible) on the Expressibility of Meibomian Glands.&#xD;
&#xD;
          4. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis,&#xD;
             anterior blepharitis, etc.) not related to MGD.&#xD;
&#xD;
          5. Subjects who have FCS total score = 15 or a score = 3, in either eye, in the superior&#xD;
             region NEI/Industry Workshop scale or subjects who have FCS with diffuse confluent&#xD;
             staining, filaments or frank epithelial defects.&#xD;
&#xD;
          6. Have suspected ocular fungal, viral or bacterial infection.&#xD;
&#xD;
          7. Have had penetrating intraocular surgery in the past 90 days or require penetrating&#xD;
             intraocular surgery during the study.&#xD;
&#xD;
          8. Have had ocular surface surgery within 12 months of Visit 1 (e.g., LASIK, refractive,&#xD;
             pterygium removal).&#xD;
&#xD;
          9. Subjects who within the past 90 days have had cauterization of the punctum or changes&#xD;
             to the status (insertion or removal) of punctal plug(s) before the Screening Visit.&#xD;
&#xD;
         10. Have used topical ocular or oral antibiotics within 30 days of the study or expect to&#xD;
             use during the study.&#xD;
&#xD;
         11. Have used LipiFlow or hypochlorous acid spray within 30 days of the study or expect to&#xD;
             use during the study.&#xD;
&#xD;
         12. If using inhaled or intranasal corticosteroids, unable to maintain a stable dose for&#xD;
             the duration of the study.&#xD;
&#xD;
         13. Have ever used isotretinoin.&#xD;
&#xD;
         14. If using Omega-3 supplements, dose must be stable for 3 months prior to Visit 1 and&#xD;
             for the duration of the study.&#xD;
&#xD;
         15. Have used topical cyclosporine within 30 days of the study or during the study.&#xD;
&#xD;
         16. Have used topical lifitegrast within 30 days of the study or during the study.&#xD;
&#xD;
         17. Have used systemic corticosteroids within 30 days prior to study entry or during study&#xD;
             participation.&#xD;
&#xD;
         18. Have used topical ocular corticosteroids or ocular non-steroidal anti-inflammatory&#xD;
             drugs (NSAIDs) within 30 days prior to study entry and during study participation.&#xD;
&#xD;
         19. Have used topical ocular antihistamine and/or mast cell stabilizers within 30 days&#xD;
             prior to study entry or during study participation.&#xD;
&#xD;
         20. Are unable or unwilling to discontinue using any preserved or unpreserved topical&#xD;
             ocular medications (including artificial tears) upon Screening and for the duration of&#xD;
             the study.&#xD;
&#xD;
         21. Are unwilling to discontinue use of contact lenses during the study.&#xD;
&#xD;
         22. Are unwilling to discontinue use of cosmetic makeup applied to the eyelids or eye&#xD;
             lashes at the Screening Visit and during the study. If makeup was used, it should be&#xD;
             removed at least 12 hours prior to Visit 1.&#xD;
&#xD;
         23. Have a known hypersensitivity to minocycline, any other tetracycline antibiotic, or to&#xD;
             any of the other ingredients in the investigational product.&#xD;
&#xD;
         24. Are unable or unwilling to withhold the use of eyelid scrubs or use of mechanical&#xD;
             therapy during the study.&#xD;
&#xD;
         25. Have been diagnosed with glaucoma or are currently using any glaucoma medication.&#xD;
&#xD;
         26. Have a history of herpetic keratitis.&#xD;
&#xD;
         27. Have a concomitant ocular pathology other than condition under study assessed as&#xD;
             potentially confounding by the investigator.&#xD;
&#xD;
         28. Have a serious systemic disease or uncontrolled medical condition that in the judgment&#xD;
             of the investigator could confound study assessments or limit compliance.&#xD;
&#xD;
         29. Have been exposed to any investigational drug or investigational device within the&#xD;
             preceding 30 days.&#xD;
&#xD;
         30. Are an employee of the site that is directly involved in the management,&#xD;
             administration, or support of this study or be an immediate family member of the same.&#xD;
&#xD;
         31. Have trigger factors including conjunctivochalasis, allergic conjunctivitis, contact&#xD;
             lens intolerance, trichiasis, epithelial basement membrane dystrophy, infectious&#xD;
             keratitis or conjunctivitis.&#xD;
&#xD;
         32. Have a documented history of ocular allergies, which, in the judgment of the&#xD;
             investigator, are likely to have an acute increase in severity due to the expected&#xD;
             timing of the exposure to the allergen to which the subject is sensitive. Subjects&#xD;
             sensitive to seasonal allergens that are not expected to be present during the study&#xD;
             are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Magrath, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hovione Scientia Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical site - 4</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 16</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 12</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 13</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site 10</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 15</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 18</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 6</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 20</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 19</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 3</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 9</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 7</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 5</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 11</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 2</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 14</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 1</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 8</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 17</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <disposition_first_submitted>February 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>February 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 2, 2021</disposition_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minocycline Topical</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>MGD</keyword>
  <keyword>Meibomian Gland Disorder</keyword>
  <keyword>Anti-Bacterial Agent</keyword>
  <keyword>Anti-imflammatory Agent</keyword>
  <keyword>Minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

